Role of the nitric oxide donor sodium nitroprusside in the antidepressant effect of ketamine in mice.
Miriam A Vogt, Anne S Vogel, Natascha Pfeiffer, Peter Gass, Dragoš Inta
European Neuropsychopharmacology October 1, 2015 DOI: 10.1016/j.euroneuro.2015.06.012 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical experimental study Peer reviewed |
|---|---|
| Population | Mice |
| Interventions | Sodium nitroprusside Ketamine |
| Dose | SNP 0.5-1 mg/kg i.p.; ketamine 30 mg/kg |
| Topics | Depression Ketamine Esketamine |
| Keywords | Nmda receptor Nitric oxide Psychosis |
| Key findings | Pre-treatment with SNP did not alter the antidepressant effect of ketamine in mice, suggesting differential involvement of the nitrinergic system in ketamine's antidepressant versus psychotomimetic effects. |
Abstract
Ketamine may represent an efficient alternative antidepressant with rapid therapeutic onset; however, the clinical use of ketamine is hampered by psychosis-like side-effects. Recent studies suggest that the nitric oxide (NO) donor sodium nitroprusside (SNP) prevents psychosis-like abnormalities triggered by ketamine or another NMDA receptor (NMDAR) antagonist, phencyclidine (PCP) in rats. SNP was shown to elicit antipsychotic effects also in humans. Considering the tight interrelation between NMDAR activation and neuronal NO synthesis, we evaluated the effect of pre-treatment with SNP on the antidepressant action of ketamine. We found that SNP (0.5-1mg/kg, i.p.) did not alter the antidepressant effect of ketamine (30 mg/kg) in the Porsolt Forced Swim Test (FST) in mice. Additionally, SNP by itself produced no effect in the FST or in the openfield. This suggests indirectly a differential involvement of the nitrinergic system in the antidepressant vs. psychotomimetic effect of ketamine, although an influence of species-specific differences cannot be excluded in this interpretation.
Comparable studies
Other preclinical and animal studies on ketamine for depression, most cited first.
Citations in the library
Cited by 2
Cites 5
- Glutamate Receptor Antagonists as Fast-Acting Therapeutic Alternatives for the Treatment of Depression: Ketamine and Other Compounds The Annual Review of Pharmacology and Toxicology January 6, 2014
- Nitric oxide involvement in the antidepressant-like effect of ketamine in the Flinders sensitive line rat model of depression Acta Neuropsychiatrica April 1, 2015
- Differential c-Fos induction by different NMDA receptor antagonists with antidepressant efficacy: potential clinical implications. The International Journal of Neuropsychopharmacology September 2009
- Behavioral effects of ketamine and toxic interactions with psychostimulants BMC Neuroscience March 16, 2006
- Blockade of phencyclidine-induced effects by a nitric oxide donor. British Journal of Pharmacology July 1, 2000